{"id":"albutoin","rwe":[{"pmid":"30726065","year":"2019","title":"Thiourea Modified Doxorubicin: A Perspective pH-Sensitive Prodrug.","finding":"","journal":"Bioconjugate chemistry","studyType":"Clinical Study"},{"pmid":"4206927","year":"1974","title":"Evaluation of albutoin as an antiepileptic drug.","finding":"","journal":"Clinical pharmacology and therapeutics","studyType":"Clinical Study"},{"pmid":"5451364","year":"1970","title":"Pharmacologic interactions of albutoin with other anticonvulsant drugs.","finding":"","journal":"The Journal of pharmacology and experimental therapeutics","studyType":"Clinical Study"},{"pmid":"4901181","year":"1969","title":"Clinical evaluation of albutoin.","finding":"","journal":"Neurology","studyType":"Clinical Study"},{"pmid":"4959915","year":"1967","title":"Albutoin, a new thiohydantoin derivative for grand mal epilepsies. Comparison with diphenylhydantoin in a double-blind, controlled study.","finding":"","journal":"Neurology","studyType":"Clinical Study"}],"tags":[{"label":"albutoin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"euprax","offLabel":[],"synonyms":["albutoin","euprax"],"timeline":[],"brandName":"Euprax","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"albutoin","explanation":"Imagine your body's physiological processes as a complex orchestra. Euprax is like a conductor that helps the different parts of the orchestra work together in harmony, leading to a desired outcome. By modulating these processes, Euprax can help alleviate certain symptoms or conditions.","oneSentence":"Euprax works by interacting with specific biological pathways to produce its therapeutic effects.","technicalDetail":"Euprax is a small molecule that binds to specific receptors or enzymes, triggering a cascade of downstream effects that ultimately lead to its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/106","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALBUTOIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:33:41.692634","biosimilars":[],"competitors":[],"genericName":"albutoin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"475NGR2DC1","CHEBI":"CHEBI:134885","INN_ID":"1449","UMLSCUI":"C0051108","ChEMBL_ID":"CHEMBL327235","KEGG_DRUG":"D02797","PUBCHEM_CID":"3032361","MESH_SUPPLEMENTAL_RECORD_UI":"C006443"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2019 Mar 20","pmid":"30726065","title":"Thiourea Modified Doxorubicin: A Perspective pH-Sensitive Prodrug.","journal":"Bioconjugate chemistry"},{"date":"1974 Apr","pmid":"4206927","title":"Evaluation of albutoin as an antiepileptic drug.","journal":"Clinical pharmacology and therapeutics"},{"date":"1970 Aug","pmid":"5451364","title":"Pharmacologic interactions of albutoin with other anticonvulsant drugs.","journal":"The Journal of pharmacology and experimental therapeutics"},{"date":"1969 Dec","pmid":"4901181","title":"Clinical evaluation of albutoin.","journal":"Neurology"},{"date":"1967 Feb","pmid":"4959915","title":"Albutoin, a new thiohydantoin derivative for grand mal epilepsies. Comparison with diphenylhydantoin in a double-blind, controlled study.","journal":"Neurology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Euprax, also known as Albutoin, is a small molecule drug in the albutoin class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating certain physiological processes. Euprax is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is unclear. As a result, there is limited information available on its safety profile and pharmacokinetic properties. Further research is needed to fully understand the properties and potential uses of Euprax.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}